Communiqués de presse BioNTech Investor News Santé & sciences de la vie — Flux RSS et veille en direct
PPN World suit le flux RSS de BioNTech Investor News en temps réel — 4 communiqués indexés au cours des 30 derniers jours, le plus récent est arrivé il y a 6 j. Suivez-le avec alertes sur recherches enregistrées, résumés IA et recherche plein texte, ou branchez l'URL RSS ci-dessous dans votre propre lecteur.
À propos de ce fil
BioNTech Investor News fait partie des 1,400+ fils de presse que PPN World surveille en continu — un fil en anglais axé sur le secteur Santé & sciences de la vie, classé sous « Allemagne » dans notre index par pays. Chaque communiqué est dédupliqué, géolocalisé et enrichi d'un résumé IA, et vous pouvez y attacher des alertes sur recherches enregistrées. BioNTech Investor News est un fil spécialisé à faible volume — 4 communiqués dans les 30 derniers jours : le genre de source qui mérite une alerte plutôt qu'un défilement.
Suivez BioNTech Investor News en temps réel dans PPN World
Chaque communiqué de BioNTech Investor News arrive dans le cockpit quelques secondes après sa publication — dédupliqué, classé, avec alertes sur recherches enregistrées et résumés IA, aux côtés de 1,400+ autres fils. Essai gratuit de 72 h, sans carte.
Commencer l'essai gratuit →Derniers communiqués de BioNTech Investor News
- BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026il y a 6 j
Pumitamig plus B7H3-targeting elfetabart drozuntecan delivers the first data in lung cancer for any PD-(L)1xVEGF bispecific immunomodulator combined with an antibody-drug conjugate, underscoring BioNT…
- BioNTech Announces Second Quarter 2026 Financial Results and Corporate Updateil y a 22 j
Guido Oelkers, Ph.D., appointed to BioNTech Management Board as Chief Executive Officer, taking office by February 1, 2027, at the latest Advanced diversified pipeline now with 14 ongoing pivotal clin…
- BioNTech Announces Second Quarter 2026 Financial Results and Corporate Updateil y a 22 j
Conference call and webcast scheduled for August 4, 2026, at 8:00 a.m. EDT (2:00 p.m. CEST)
- BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officeril y a 23 j
Mainz, Germany, August 3, 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that its Supervisory Board has appointed Guido Oelkers, Ph.D., to the Manageme…
- BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officeril y a 23 j
Mainz, Germany, August 3, 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that its Supervisory Board has appointed Guido Oelkers, Ph.D., to the Manageme…
- European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Unionil y a 28 j
Data indicate that the 2026-2027 COVID-19 vaccine formula, targeting the XFG variant, induces a strong immune response against contemporary circulating and emerging lineages More than five billion dos…
- BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026il y a 36 j
MAINZ, Germany, July 21, 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the second quarter 2026 on Tuesday, August 4, 2026. Add…
- BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026il y a 36 j
MAINZ, Germany, July 21 , 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the second quarter 2026 on Tuesday, August 4, 2026. Ad…
- Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trialil y a 88 j
First investigational PD-(L)1xVEGF bispecific immunomodulator to present global data showing encouraging efficacy in combination with chemotherapy in first-line non-small cell lung cancer across PD-L1…
- BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meetingil y a 96 j
Pumitamig data from the ongoing Phase 2/3 ROSETTA Lung-02 trial in first-line non-small cell lung cancer mark the third global data set to consistently show encouraging anti-tumor activity for pumitam…
- BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meetingil y a 96 j
Pumitamig data from the ongoing Phase 2/3 ROSETTA Lung-02 trial in first-line non-small cell lung cancer mark the third global data set to consistently show encouraging anti-tumor activity for pumitam…
- BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026il y a 103 j
MAINZ, Germany, May 15, 2026 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) held its Annual General Meeting (“AGM”) today. A total of 92 per cent of the share capital was…
Les plus récents communiqués de ce fil défilent en direct pour les membres PPN World.
Questions fréquentes
Comment suivre les communiqués de BioNTech Investor News en temps réel?+
À quelle fréquence les communiqués de BioNTech Investor News sont-ils relevés?+
Quel type de communiqués BioNTech Investor News publie-t-il?+
Fils liés
- Presseportal
- PR-Inside
- lifePR (DE)
- PresseBox (DE)
- German Federal Government (Bundesregierung)
- Bayerische Staatsregierung (Bayerisches Landesportal)
- Medienservice Sachsen
- Baden-Württemberg Landesregierung (Alle Meldungen)
- Sachsen-Anhalt Landesportal (Pressemitteilungen der Ministerien)
- Schleswig-Holstein Landesregierung (Alle Medieninformationen)